CD24 exosomes - OBCTCD24
Alternative Names: Coven D24; EXO-CD24Latest Information Update: 28 Jun 2025
At a glance
- Originator OBCTCD24
- Developer Nano24; OBCTCD24
- Class Anti-inflammatories; Biological proteins; Exosome therapies
- Mechanism of Action Immunosuppressants; Protein replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Adult respiratory distress syndrome; COVID 2019 infections
- No development reported Autoimmune disorders; Respiratory tract infections
Most Recent Events
- 28 Jun 2025 No recent reports of development identified for preclinical development in Autoimmune-disorders in Israel
- 28 Jun 2025 No recent reports of development identified for preclinical development in COVID-2019-infections in Israel (Inhalation, Suspension)
- 28 Jun 2025 No recent reports of development identified for preclinical development in Respiratory-tract-infections in Israel